Leaders from Drug Delivery Industry to Discuss Advances in Biotech, Nanotech and Targeted Delivery Technologies at Arrowhead's 3rd Annual Drug Delivery Summit

Share Article

Arrowhead's 3rd Annual Drug Delivery Summit, scheduled to take place in San Francisco, CA on May 14th and May 15th, 2009, will be bringing together leaders from the drug delivery industry to discuss the newest and most important advances being made in the field of drug delivery.

Arrowhead's 3rd Annual Drug Delivery Summit, scheduled to take place in San Francisco, CA on May 14th and May 15th, 2009, will be bringing together leaders from the drug delivery industry to discuss the newest and most important advances being made in the field of drug delivery. Moreover, the commercial, regulatory and legal issues facing the impending commercialization of these innovative new technologies will be discussed at length.

The burgeoning market for biologics and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for the drug delivery industry. Not only are the delivery of proteins, peptides, insulin and vaccines being revolutionized by new drug delivery technologies, but novel therapeutic approaches, such as RNAi and targeted cancer therapies are being shaped by new drug delivery systems in development.

Arrowhead's 3rd Annual Drug Delivery Summit will provide an:

  • Assessment of new technologies in development for the delivery of proteins, peptides and siRNA, (RNAi)
  • A critical examination of key emerging technologies in injectable, inhalable / pulmonary, transdermal, nanotechnology, transmucosal, oral, med-device combination products and other novel delivery routes

Attendees will come away from this conference with a better understanding the clinical, regulatory, legal and commercial issues facing novel drug delivery technologies and their application in biologics and targeted therapies. Attendees will also gain a better sense of the implications of the biotech revolution on the drug delivery industry.

View the full agenda Here

Register Here

Key speakers at this year's summit include:
John S. Patton, Ph.D., Co-Founder of Nektar Therapeutics and the Founder and CEO of Dance Pharmaceuticals, who will discuss the controversial topic of inhaled insulin and argue why he believes that a lack of success in the commercial market does not necessarily indicate a failure for this revolutionary delivery technology.

Ed Maggio, Ph.D., CEO of Aegis Therapeutics, a company focused on the commercialization of both advanced patented drug delivery, and protein stabilization technologies. Dr. Maggio will be discussing the advances made and the challenges facing the non-invasive delivery of peptides, proteins, and other macromolecules via intranasal and other transmucosal routes.

Randall Mrsny, Ph.D., former Head of Genentech's Drug Delivery/Biology Lab, the Founder of Trinity Biosystems, the Founder and current Chief Scientific Officer of Unity Therapeutics, and Professor of Epithelial Biology at the University of Bath, UK, who will discuss his research in intracellular peptide drug delivery for epithelial-derived cancers.

Other notable speakers include:
James Fink, PhD, RRT, FAARC, Independent Consultant, Member of Scientific Advisory Board, Aerogen
Yael Weiss, MD, Ph.D, Director Licensing and External Research, Merck & Co.
Andrew Luk, Ph.D., Sr. Director, West Coast Product Development, Convergent Product Development, Cordis Corporation, Johnson & Johnson
Steve Damon, Sr. VP Business Development, Altea Therapeutics
Jose Lebron, Ph.D., Sr. Investigator of Safety Assessment, Merck (Sirna Therapeutics)
Dr. Bob Irving, Chief Operating Officer, NanoVentures Australia Ltd
Niraj Vasisht, Ph.D, Vice President, Product Development, BioDelivery Sciences
Gerben Moolhuizen, Chief Business Officer, Octoplus
Dr. David Owen, BSc (Hons), PhD, Vice President, Research, Starpharma
Kirk Seward, Co-Founder, Director, President and Chief Technology Officer, Mercator MedSystems
Seth Feuerstein, MD, JD, President, Carigent Therapeutics
Michael Swit, Esq., Vice President, The Weinberg Group
Raj Bawa, PhD, Patent Agent, Bawa Biotechnology Consulting, Adjunct Associate Professor, Rensselaer Polytechnic Institute
Mark Bunger, Director of Research, Lux Research
Pascal Deschatelets, Co-Founder and Chief Operating Officer, Potentia Pharmaceuticals
Ajay Rastogi, Vice President, Technology Catalysts International
Jared Hahn, Technical Operations Manager, Technology Catalysts International

For more information about this conference, please visit arrowheadpublishers.com or call 1-312-244-3703.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author